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Urogenital schistosomiasis, due to Schistosoma haematobium, is endemic in sub-Saharan Africa. Control is by targeted treatment
with praziquantel but preschool age children are excluded from control programs. Immunological studies on the effect of treatment
at this young age are scarce. In light of studies in older individuals showing that praziquantel alters antischistosome immune
responses and responses to bystander antigens, this study aims to investigate how these responses would be affected by treatment
at this young age. Antibody responses directed against schistosome antigens, Plasmodium falciparum crude and recombinant
antigens, and the allergen house dust mite were measured in children aged 3 to 5 years before and 6 weeks after treatment. The
change in serological recognition of schistosome proteins was also investigated. Treatment augmented antischistosome IgM and IgE
responses. The increase in IgE responses directed against adult worm antigens was accompanied by enhanced antigen recognition
by sera from the children. Antibody responses directed against Plasmodium antigens were not significantly affected by praziquantel
treatment nor were levels of allergen specific responses. Overall, praziquantel treatment enhanced, quantitatively and qualitatively,
the antiworm responses associated with protective immunity but did not alter Plasmodium-specific responses or allergen-specific
responses which mediate pathology in allergic disease.
1. Introduction
Schistosomiasis is amajor human helminth infection endem-
ic in developing countries where children harbor the great-
est number of parasites. Urogenital schistosomiasis, caused
by infection with S. haematobium, is the most preva-
lent in sub-Saharan Africa and affected children suffer
stunted growth, impaired memory and cognitive develop-
ment, anemia, haematuria, and reduced physical fitness.
Current control programs target school children, typically
aged 6 years old and above and younger pre-school age
children (i.e., 5 years and below) are not treated. This
is partly because they have been regarded as being at
very low risk of infection and infection-associated mor-
bidity and partly because, until recently, there has been
lack of safety data on praziquantel in this age group [1].
Yet, the reality is that exclusion of these children from
control programs leaves them at high risk of developing
chronic pathology as has been shown in high endemic foci
[2].
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This health inequality is now being addressed with the
realization that preschool age children do experience sig-
nificant levels of infection [3–7]. The WHO has recently
formally recognized that these children should be considered
for treatment [8] and studies on the safety and efficacy
of praziquantel, as well as methods of diagnosis and drug
delivery in this age group [6, 9–11], have been carried out.
The next stage is to assess the consequences of praziquantel
treatment beyond the reduction of infection, particularly the
effects on schistosome-specific responses as well as responses
to bystander antigens.
Indeed, praziquantel treatment of school children and
adults has been shown to enhance immune responses asso-
ciated with resistance to reinfection with schistosomes in
endemic areas [12, 13] but immunological studies in pre-
school children are scarce. Moreover, antihelminthic treat-
ment has been associated with an increase in atopy [14,
15], as a result of alterations in the immunological balance
established by the parasites. These studies were conducted
in schoolchildren and the effect of antihelminthic treatment
on allergic sensitization in younger children remains to be
determined.
Schistosome infections have also been reported to both
exacerbate and ameliorate responses associated with resis-
tance to Plasmodium falciparum, the causative agent of
malaria [16, 17]. Nonetheless, previous studies in schoolchil-
dren aged 6–18 years old showed that antihelminthic treat-
ment of S. haematobium infection did not alter immune
responses to the malaria vaccine candidates merozoite sur-
face protein (MSP) 1 and 2 [18]. It remains to be determined
if this is the case in younger children.
Thus, the first aim of this study was to determine the
short-term antihelminthic effects on immunological markers
of exposure to schistosome (IgM directed against schisto-
some cercariae, egg, and adult worms [19]) and malaria (IgM
directed against Plasmodium total schizont [20]) infections as
well as the effects on antibody responses associatedwith resis-
tance to infection/reinfection (IgE and IgG4 directed against
schistosome cercariae, egg, and adult worms, IgG directed
against Plasmodium vaccine candidates MSP-1 and MSP-2
[16, 21–23]) in children aged 3–5 years in Zimbabwe. We also
determined the effects of antihelminthic treatment on allergic
sensitization to the house dustmiteD. pteronyssinus, themost
prevalent allergen in Zimbabwe [24].
The second aim of this study was to identify antigens
serologically recognized on the adult worm by these children
(individually) both before and 6 weeks after treatment, to
assess whether antischistosome antibody changes following
treatment were due to qualitative changes in antigens recog-
nised by the host immune system as has been shown in adults
[25].
2. Materials and Methods
2.1. Study Population. The study population was recruited
fromMagaya, Chitate, andChipinda villages in theMashona-
land East Province of Zimbabwe where S. haematobium
is endemic. Populations from the 3 villages and selection
criteria have been described elsewhere [9, 26, 27]. Forty-
one (41) children were included in this study; 31 had
received praziquantel treatment while 10 children, whose
parents declined treatment for religious reasons, formed the
untreated control group. All the treated children who were
egg positive at baseline (𝑛 = 4) had cleared infection at
the six weeks follow up. There was no significant difference
between treated/untreated children in terms of village of
residence (𝑍 = −1.037, 𝑃 = 0.463) and their parents were
all subsistent farmers. All the children were also part of a
larger study investigating the safety of praziquantel and they
reported no adverse effects 24 hours following treatment [9].
Three children provided enough blood samples to enable
proteomic analyses on schistosome antigens serologically
recognised before versus after treatment. One of them was in
the untreated group and served as a negative control. All the 3
children were excreting schistosome eggs in urine at baseline.
2.2. Ethical Statement. Permission to conduct the study in the
region was obtained from the Provincial Medical Director.
Institutional and ethical approval was received from the
University of Zimbabwe and theMedical Research Council of
Zimbabwe respectively. In addition, the study received ethical
approval from the World Health Organization’s Research
Ethics Review Committee. At the beginning of the study,
parents and guardians of participating children had the aims
and procedures of the project explained fully in the local
language, Shona, and written consent was obtained from par-
ticipants’ parents/guardians before enrolment into the study.
After collection of all samples, all compliant participants were
offered anti-helminthic treatment with the recommended
dose of praziquantel (40mg/kg of body weight).
2.3. Antigens. Lyophilized soluble S. haematobium adult
(SWAP), cercariea (CAP), and egg (SEA) antigens were
obtained from the Theodor Bilharz Institute (Giza, Egypt)
and reconstituted in ultra pure water as recommended
by the manufacturer. D. pteronyssinus Derp1 allergen was
obtained from Indoor Biotechnologies. Crude P. falciparum
schizont antigens were of theWellcome strain of the parasite.
Recombinant antigens (from Plasmodium merozoite surface
protein, MSP) were MSP-1
19
antigen, the 19 kDa C-terminal
domain of MSP1, and MSP-2 which has 2 serotypes: CH150
that belongs to serotype A (3D7-like), and Dd2 that belongs
to serotype B (FC27-like) [28].
2.4. Antibody Assays. A standard indirect enzyme-linked
immunosorbent assay (ELISA) was optimized as described
previously [26, 27] and used to quantify levels of antibodies
directed against SWAP, SEA, and CAP (IgM, IgE, and IgG4);
P. falciparum antigens (IgM and IgG), and Derp 1 allergen
(IgE and IgG4) both before and 6 weeks after treatment.
For schistosome-specific antibodies, microtitre plates
were coated overnight at 4∘C with 100𝜇L/well of antigen
at 5 𝜇g/mL (10𝜇g/mL for SEA) in carbonate bicarbonate
buffer (pH = 9.6) and then washed once with PBS/0.03%
Tween20 (which was used for all subsequent washes). Plates
were blocked with 5% skimmedmilk in PBS/0.03% Tween20.
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100 𝜇L of the serum samples was then added diluted at 1 : 20
for IgE (anti-SEA, SWAP and CAP); 1 : 100 for IgM anti-
SWAP and IgG4 anti-CAP and SWAP; 1 : 400 for IgM anti-
CAP and SEA and IgG4 anti-SEA. Plates were incubated for
2 hours at 37∘C. After washing 3 times, 100𝜇L of antihuman
horse-radish peroxide conjugated IgE (Sigma), IgM (Dako)
or IgG4 (The Binding Site) was added diluted (with blocking
buffer) at 1 : 1000 except for IgM anti-SWAP (1 : 2000), IgG4
anti-CAP and SWAP (1 : 500), and IgE anti-SWAP (1 : 250).
After 1 hour incubation at 37∘C followed by 6 washes, 100 𝜇L
of the substrate (ABTS) was added.The reactionwas stopped,
using 25%HCL, after 15min incubation at room temperature
for IgM and IgG4 and 30min incubation at 37∘C for IgE.
Absorbance readings of all wells were performed at 405 nm.
For Plasmodium-specific responses, the same protocol
was followed but 50𝜇L/well of 1𝜇g/mL (crude schizont) or
50 ng/mL (recombinant antigens) was used to coat plates.
All samples were diluted 1 : 100 for all assays and secondary
antibodies (Sigma) diluted 1 : 1000 (IgM and IgG) for crude
antigens and 1 : 2000 (IgG) for recombinant antigens.The col-
orimetric reaction time was 15 minutes at room temperature
for all assays.
For Derp1-specific responses, plates were coated with
50 𝜇L/well of 5𝜇g/mL and samples diluted 1 : 10. Detection
antibodies (IgE from Sigma and IgG4 fromThe Binding Site)
were diluted 1 : 1000 and the reaction time for the substrate
was 30 minutes at 37∘C.
All laboratory assays for the pre- and posttreatment time
points were run at the same time and by the same individual.
All samples were assayed in duplicate and 3 sera from
European children (negative controls) who have never been
exposed to schistosome or malaria infections were included
on each plate and were used to set up cutoff points for IgM
status (ODs of 0.2, 0.24, and 0.55, resp., for SWAP, CAP, and
SEA). A blank control containing no sera was included in
duplicate on each plate and the background absorbance of
reagents in the absence of serum was subtracted from all
readings. A pool of responders (positive controls) was run on
each plate and readings were comparable across plates; that
is, the % CVs were less than 20% for all comparisons and
readings were below the critical values as determined by Reed
et al. [29]; therefore no correction factor was used. Antibody
levels were expressed as optical densities.
2.5. Gel Electrophoresis. A 1-dimensional gel separation was
performed. One hundred 𝜇g of antigen (SWAP), diluted
1 : 1 in lithium dodecyl sulphate, was run on a 10% gel
using sodium dodecyl sulphate (SDS) buffer. The gel (7 cm)
was subsequently divided longitudinally into 2 parts, the
first to be used for Western blotting and the second for
protein identification. The same gel for Western blot and
protein identification was used to exclude variations due to
experimental settings. The proteins on the piece of gel used
for identificationwere stainedwith silver nitratewhile the rest
were transferred onto a 0.45 𝜇m nitrocellulose membrane.
2.6. Western Blotting. Proteins were transferred onto a
nitrocellulose membrane using a wet system, in transfer
buffer made of 20% methanol, 25mM Tris, and 192mM
Glycine. The membrane was then blocked with 2% BSA
in TBS/0.05% Tween20 for 3 hours, washed 2 times in
TBS/0.05% Tween/0.2% triton x-100, and cut into strips.
On each strip, 1.5mL of individual serum diluted 1 : 50 in
blocking solution was added and all strips were incubated
overnight at 4∘C. After 3 washes, 1.5mL of HRP-conjugated
IgE antibody (Sigma) was added and the strips incubated
for 2 hours at room temperature. After 4 washes, the strips
were incubated in ECL Plus reagent system for 5 minutes,
before being exposed on hyperfilm. The film was developed
and bands were matched to those on the silver-stained piece
of gel.
2.7. Mass Spectrometry. Bands on the silver stained piece of
gel that matched those on the Western blots were excised,
reducedwith Farmer’s reagent, and subjected to in-gel trypsin
digestion using standard protocols [30]. The resulting tryptic
peptides were solubilized in 0.5% formic acid and fraction-
ated on a nanoflow uHPLC system (Thermo RSLCnano).
Peptide separation was performed on a Pepmap C18 reversed
phase column (LC Packings), using a 5–85% v/v acetonitrile
gradient (in 0.5% v/v formic acid) run over 45min at a flow
rate of 0.2 uL/min. Eluate was analysed by online electrospray
ionisation (ESI)mass spectrometry using anAmazon ion trap
MS/MS (BrukerDaltonics) operating a continuous duty cycle
of survey MS scan followed by up to five MS/MS analyses
of the most abundant peptides, choosing the most intense
multiply charged ions with dynamic exclusion for 120 s.
MS data was processed using Data Analysis software
(Bruker) and the automated Matrix Science Mascot Daemon
server (v2.1.06). Protein identifications were assigned using
the Mascot search engine to interrogate Schistosome protein
sequences in the NCBInr database, allowing a mass tolerance
of 0.3Da for both MS and MS/MS analyses.
2.8. Statistical Analysis. Since the data did not fulfill the
assumptions for parametric tests and data transformations
could not overcome this, nonparametric tests were used for
all statistical analyses. The nonparametric Wilcoxon signed-
rank tests for paired samples were performed to compare
pre- and posttreatment antibody raw data (optical densities),
ratios (IgE/IgG4), and infection intensities. For comparisons
between groups of different individuals (i.e., infected versus
uninfected, IgM negative versus IgM positive, etc.), Mann-
Whitney 𝑈 tests were performed. The cutoffs for IgM anti-
schistosome or antischizont antigens were calculated as the
mean absorbance plus 2 standard deviations of readings
from European negative controls. All statistical analyses were
conducted in PASW statistics (formerly SPSS) 17 and𝑃 values
of <0.05 were considered significant. A sequential Bonferroni
correction was used to identify results that were significant in
the context of the multiple statistical comparisons [31].
3. Results
3.1. Infection and Antibody Levels before Antihelminthic Treat-
ment. At baseline, 38 children provided urine samples and
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Table 1: Characteristics of the study groups at baseline.
Treated Untreated Difference (𝑍 and 𝑃 value or 𝜒2)
Mean age (years) 4.5 4.7 −1.341, 0.247
Mean infection intensity (eggs/10mL) 10 8.1 −0.146, 0.946
(Prevalence in %) 13.2 11.1 𝜒2 = 0.043, 𝑃 = 0.835
Residence 9/14/8 7/2/1 −1.037, 0.063
Male/female 9/22 4/10 −0.640, 0.622
SWAP-IgM (OD ± SEM) 0.155 ± 0.03 0.172 ± 0.02 −1.548, 0.127
Prevalence in % 14.6 7.3 𝜒2 = 0.5, 𝑃 = 0.479
CAP-IgM (OD ± SEM) 0.225 ± 0.036 0.333 ± 0.06 −1.913, 0.057
Prevalence in % 26.8 12.2 𝜒2 = 0.67, 𝑃 = 0.4
SEA-IgM (OD ± SEM) 0.345 ± 0.04 0.513 ± 0.1 −1.312, 0.198
Prevalence in % 7.5 10 𝜒2 = 4.67, P = 0.03
SWAP-IgE (OD ± SEM) 0.054 ± 0.02 0.054 ± 0.02 −0.972, 0.345
CAP-IgE (OD ± SEM) 0.077 ± 0.02 0.154 ± 0.1 −0.245, 0.823
SEA-IgE (OD ± SEM) 0.106 ± 0.05 0.151 ± 0.06 −0.473, 0.643
SWAP-IgG4 (OD ± SEM) 0.083 ± 0.05 0.028 ± 0.01 −0.945, 0.376
CAP-IgG4 (OD ± SEM) 0.019 ± 0.07 0.008 ± 0.02 −1.031, 0.355
SEA-IgG4 (OD ± SEM) 0.123 ± 0.05 0.019 ± 0.009 −1.714, 0.087
Derp-IgE (OD ± SEM) 0.049 ± 0.02 0.037 ± 0.007 −1.337, 0.190
Derp-IgG4 (OD ± SEM) 0.048 ± 0.016 0.243 ± 0.13 −1.286, 0.211
Schizont-IgM (OD ± SEM) 0.098 ± 0.01 0.145 ± 0.02 −1.901, 0.056
Schizont-IgG (OD ± SEM) 0.058 ± 0.02 0.028 ± 0.009 −0.968, 0.343
DD2-IgG (OD ± SEM) 0.034 ± 0.007 0.149 ± 0.09 −1.600, 0.119
MSP119-IgG (OD ± SEM) 0.029 ± 0.01 0.013 ± 0.004 −0.402, 0.721
CH150-IgG (OD ± SEM) 0.018 ± 0.005 0.005 ± 0.003 −0.987, 0.343
Comparison of treated and untreated groups in terms of baseline infection levels, demographic, and immunological characteristics. OD: optical density, SEM:
standard error of mean. The 𝑍 and 𝑃 values were calculated using the Mann-Whitney 𝑈 (2 samples) test, and prevalences were compared using the 𝜒2 test.
The significant value is highlighted in bold.
13.2% (CI
95
4.4–28) were schistosome egg positive (mean egg
count of 10 eggs/10mL). Of the 41 children included in this
study, 17.5% (CI
95
7.3–32.8) showed immunological evidence
of recent exposure to egg antigens (positive anti-SEA IgM),
39% (CI
95
24.2–55.5) to cercariae antigens (positive anti-CAP
IgM), and 22% (CI
95
10.6–37.6) to adult schistosome antigens
(positive anti-SWAP IgM).
None of the children were P. falciparum positive as
determined by thin and thick smears or by the Paracheck
serological test but 21% (CI
95
7.1–42.1) showed immunological
evidence of recent exposure to parasite antigens (positive
anti-schizont IgM). No significant difference in Plasmodium-
specific antibody levels was observed between schistosome
egg positive versus egg negative children (𝑍 = −0.132, 𝑃 =
0.935; 𝑍 = −0.742, 𝑃 = 0.505; 𝑍 = −0.579, 𝑃 = 0.62;
𝑍 = 1.354, 𝑃 = 0.202; 𝑍 = −1.180, 𝑃 = 0.271, resp.,
for MSP119, DD2, CH150, Schizont-IgM, and Schizont IgG).
Similarly, there was no significant difference in levels of
Derp1-specific responses between schistosome egg positive
versus egg negative (𝑍 = −0.173, 𝑃 = 0.4315; 𝑍 = −1.152,
𝑃 = 0.1245; 𝑍 = −1.36, 𝑃 = 0.087, resp., for IgE, IgG4, and
IgE/IgG4 ratio).
3.2. Effects of Praziquantel Treatment on Antibody Levels. At
baseline, there was no significant difference inmean antibody
levels (all isotypes) between children who were subsequently
treated and thosewhowere not. Furthermore, infection levels
were comparable between the two groups (𝑍 = −0.146, 𝑃 =
0.884 for mean infection intensity and 𝜒2 = 0.043, 𝑃 = 0.662
for prevalence).
Six weeks after treatment, all of the treated children were
schistosome egg negative (all the egg positive children had
cleared infection), resulting in a significant fall in the mean
egg count (𝑍 = −1.626, 𝑃 = 0.034). On the other hand,
infection intensity increased for the one child who was egg
positive at baseline in the untreated group (73 to 166 eggs
per 10mL). There were no newly infected children in the
untreated group. There were significant changes in levels of
the majority of antibodies in the treated children between
the two time points as shown in Table 2 and detailed below.
Overall, the percentage of children with positive CAP- and
SWAP-IgM (marker of exposure) increased after treatment
(39% to 63.4% and 22% to 43.9%, resp.).
3.2.1. Schistosome-Specific Antibody Levels. Adult schisto-
some worm and cercariae-specific IgM titers, but not egg-
specific IgM, rose significantly in treated children (Fig-
ure 1(a)). Similarly, adult worm and egg-specific IgE titers also
increased significantly following treatment (Figure 1(b)). The
figures (Figures 1(a) and 1(b)) further illustrate that there was
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Table 2: Results from the non-parametric Wilcoxon signed-rank tests.
Antibody isotype Treated group Untreated group
CAP-IgM −4.037 (<0.000) −0.357 (0.36)
SWAP-IgM −2.626 (0.0045) −0.533 (0.297)
SEA-IgM −0.987 (0.162) −0.357 (0.361)
CAP-IgE −0.683 (0.247) −0.296 (0.383)
Antischistosome responses SWAP-IgE −2.633 (0.004) −0.968 (0.166)
SEA-IgE −2.747 (0.003) −1.599 (0.055)
CAP-IgG4 −0.35 (0.363) −0.106 (0.458)
SWAP-IgG4 −2.018 (0.022) −0.415 (0.339)
SEA-IgG4 −0.718 (0.237) −2.601 (0.003)
Antiallergen responses Derp-IgG4 −3.746 (<0.000) −1.96 (0.025)
Derp-IgE −3.497 (<0.000) −0.968 (0.166)
Schizont-IgM −2.308 (0.01) −1.992 (0.023)
Antiplasmodium responses
Schizont-IgG −2.222 (0.013) −0.734 (0.231)
CH150-IgG −2.103 (0.018) −1.473 (0.705)
MSP119-IgG −2.043 (0.021) −1.897 (0.029)
Dd2-IgG −3.333 (0.0005) −1.992 (0.023)
𝑍 and 𝑃 values from the nonparametric Wilcoxon signed-rank tests comparing pre- and posttreatment antibody levels are shown for each antibody isotype.
Significant results (𝑃 < 0.05) are highlighted in bold and those significant after Bonferroni-adjustmentin italic font. CAP: cercariae antigen preparation, SWAP:
soluble worm antigen preparation, and SEA: soluble egg antigen.
no clear distinction between children who were egg positive
and negative at baseline.
Overall, adult worm specific IgG4 titers (Figure 1(c))
decreased following treatment, but the decline only occurred
in children with mild infection at baseline (0.3 to 10.7 mean
eggs/10mL) and not in egg negative children. The decline
was however not statistically significant after Bonferroni
correction (Table 2).
In contrast, levels of all anti-schistosome antibodies
(except egg-specific IgG4 which declined) did not change
significantly in the 6 weeks period for untreated children
(Figures 1(a)–1(c) and Table 1). No significant changes
occurred in the ratio IgE/IgG4 against all the 3 parasite life
cycle stages (𝑍 = −1.118, 𝑃 = 0.453; 𝑍 = −1.139, 𝑃 = 0.128;
and 𝑍 = −0.02, 𝑃 = 0.492, resp., for adult worm, cercariae
and egg antigens) in either group (treated or untreated).
3.2.2. Derp1-Specific Antibody Levels. A significant increase
in IgE and IgG4 against Derp1 was observed in treated
children (Figure 2). However, an increase in IgG4 was also
observed in untreated controls. No significant change was
observed in the ratio IgE/IgG4 in both groups (𝑍 = −0.431,
𝑃 = 0.333 and 𝑍 = −0.357, 𝑃 = 0.361, resp., for treated and
untreated groups).
3.2.3. Plasmodium-Specific Antibody Levels. A decrease
occurred in titres of IgM and IgG antibodies against the total
schizont antigen following praziquantel (PZQ) treatment
(Figure 3(a)). Similarly there was a significant decline in
IgG levels against all the malaria vaccine candidates MSP-1
(MSP1
19
) and MSP-2 (Dd2 and CH150) after treatment
(Figure 3(b)). Untreated children also exhibited a decrease
in IgG against Dd2 and MSP1
19
, and IgM against the total
schizont over the same time frame.
3.3. Antigens Recognized before versus after Treatment. Gel
bands were detected by their reactivity with IgE antibodies
in serum samples. The before treatment and after treatment
Western blot assays were conducted on the same membrane
to exclude any variation that might arise from the use of
different antigen preparations. Only 1 band (∼80 kDa) was
recognized by all serum samples collected before treatment
(Figure 4). Six weeks following treatment, sera from treated
children recognized an additional band (∼100 kDa) which
was absent on the blot from the untreated child. Furthermore,
the image master analysis showed that the 80 kDa band
was enhanced after treatment (the bands were quantified by
their pixel intensities).The potential identities of the proteins
recognized, and the corresponding hit scores, are listed in
Table 3.
4. Discussion
With increasing calls for the inclusion of pre-school children
and infants in mass chemotherapy programmes for schisto-
some control [1, 4, 6, 9, 11], and studies in school children
and adults suggesting that antihelminthic treatment not only
affects immune responses directed against schistosomes but
may also affect immune responses directed against unrelated
antigens [13, 14, 32], the current study aimed to investigate
immunological consequences of praziquantel treatment in
young pre-school age children.
The study shows significant changes in the levels of
anti-schistosome adult worm IgM and IgE antibody titres
6 weeks following praziquantel treatment in children aged
6 Journal of Tropical Medicine
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Figure 1: Continued.
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Figure 1: Change in anti-schistosome antibody titers (optical densities). Serum IgM (a); IgE (b) and IgG4 (c) against adult worm (SWAP),
cercariae (CAP), and egg (SEA) antigens are plotted as lines connecting pre- (baseline) and post- (6 weeks) treatment levels for treated and
untreated children. Participants who were egg positive at baseline are highlighted in grey thick lines. Stars represent significant difference of
mean absorbencies at ∗∗𝑃 < 0.01 or ∗𝑃 < 0.05. The cut-off points for IgM are highlighted with dashed horizontal lines (a).
3–5 years old living in an S. haematobium endemic area.
Anti-schistosome egg IgE and anticercaria IgMalso increased
significantly following treatment.There was a decline in anti-
schistosome worm IgG4 levels following treatment, essen-
tially driven by children presentingwith S. haematobium eggs
in urine at baseline. However, this decline was not statistically
significant following Bonferroni correction, possibly due to
the small sample size.
A relatively small number of participants in this study
were egg positive at baseline.The change in anti-schistosome
antibody levels in children who were egg negative at base-
line suggests that these children may have had prepatent
infection, single sex infection, and/or low levels of infection
undetected by the egg count technique [33]. Indeed, recent
studies in pre-school children using a rapid diagnostic test
based on cercariae antigens indicate that infection levels
are about 3 times higher than prevalence obtained by the
egg count [34]. Consistent with these findings, the current
study shows a prevalence of 39% based on CAP-IgM, which
is 3 times higher than the 13% prevalence obtained based
on egg count. The possibility of prepatent and/or single
sex infections was further supported by the increase in the
percentage of children with positive CAP- and SWAP-IgM
after treatment.
The increase in anti-worm and anti-cercariae IgM
responses is consistent with reported changes in adult worm
(and cross-reactive) antigens exposed to the immune system
following the killing of adult worms by praziquantel [35].
Antiegg responses have been proposed as a diagnostic tool for
schistosome infections in young children where egg counts
are less reliable due to low levels of patent infection or to sin-
gle sex infections [11]. In this study, antiegg IgM responses did
not change following treatment, suggesting that while antiegg
responses may be good markers of the presence of a patent
schistosome infection before treatment, they may not be a
reliable tool for use in evaluating the efficacy of treatment.
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Figure 2: Change in anti-Derp1 antibody levels. Serum IgE and IgG4 (optical densities) against Derp1 allergen are plotted as lines connecting
pre- (baseline) and post- (6 weeks) treatment levels for treated and untreated children. Participants who were egg positive at baseline are
highlighted in grey thick lines. Stars represent significant difference of mean absorbencies at ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01.
This study showed that, consistent with findings in
older individuals [32], praziquantel treatment boosts the
anti-worm IgE immune responses associated with protec-
tion, suggesting that this young age group may also ben-
efit immunologically from anti-schistosome chemotherapy,
which reduces reinfection in older children and adults by
stimulating IgE responses [13, 32].
The increase in IgE titres was accompanied by an increase
in the number of parasite antigens recognised, suggesting that
treatment results in the enhancement of antigen recognition
as already reported for older children and adults [25].
Potential mechanisms for this include the introduction of
previously “hidden” antigens or enhanced affinitymaturation
of IgE responses. The proteins identified after treatment were
essentially constituents of the parasite surface and muscu-
lature, consistent with the praziquantel disruptive action on
them [36–38]. Among these was the myosin heavy chain,
which has been previously recognized by pooled sera from
older individuals with a longer history of infection [39]. Two
distinct fragments of this protein have previously been asso-
ciated with protection against reinfection in mice vaccinated
with radiation-attenuated cercariae [40, 41]. S. mansoni heat
shock protein 70 (HSP70) homologue was also identified,
consistent with previous results from pooled samples of
older individuals [25]. HSPs are proteins that are expressed
by all eukaryotic cells to maintain cell homeostasis under
stress conditions. Furthermore, because they are suspected
of being inducers of multiple pathways of immunity, these
proteins may be explored as potential adjuvants in vaccine
development against cancer and infections (reviewed by Segal
et al. [42]).
This approach presents the limitation that all the par-
asite antigens described were recognised by IgE. Although
parasite-specific IgE antibodies have been associated with
protection [21, 32, 43], vaccine candidates eliciting IgE
responses in helminth endemic areas have recently been
shown to induce urticaria [44]. Although “desensitization”
of the IgE-inducing vaccine is a possibility to overcome
this problem, identification of antigens recognized by other
isotypes [45] may be more realistic. Nevertheless, charac-
terising parasite antigens eliciting IgE responses gives the
information on what to “avoid” or “take with precaution” in
vaccine design. Furthermore, given the similarities between
anti-helminth and anti-allergen responses [46], comparative
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Figure 3: Change in anti-Plasmodium-falciparum antibody levels. (a) P. falciparum schizont-specific IgM and IgG (optical densities) and (b)
antibody levels (IgG) against the merozoite surface proteins MSP-1 (MSP1
19
) and MSP-2 (Dd2 and CH150) are shown as lines connecting
pre- (baseline) and post- (6 weeks) treatment levels for treated and untreated children. Participants who were egg positive at baseline are
highlighted in grey thick lines. Stars represent significant difference of mean absorbencies at ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01.
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Table 3: Potential identities of the proteins recognized.
Band Protein name Species NCBI accession no. Hit score Mass
Putative glycogen phosphorylase S. mansoni gi|360045358 564 94169
Surface protein S. mansoni gi|501209 182 190732
∼80 kDa Myosin heavy chain S. mansoni gi|256086969 159 171563
Actin S. mansoni gi|256084607 138 35652
Putative heat shock protein 70 S. mansoni gi|353229993 125 70215
Hypothetical protein Smp 208030 S. mansoni gi|353231600 53 333514
∼100 kDa GPI-anchored surface glycoprotein S. mansoni gi|256052078 129 187956
Putative glycogen phosphorylase S. mansoni gi|360045358 100 94169
The 2 bands on silver stain that matched those identified on immunoblots were excised and subjected to trypsin digestion before being analysed by mass
spectrometry.The list of Schistosome sequences (fromNCBI database) that matched the peptide masses on the bands is indicated with the corresponding ions
scores. Ions score is 10∗ Log (𝑃), where 𝑃 is the probability that the observed match is a random event. Individual ions scores >41 indicate identity or extensive
homology (𝑃 < 0.05). The highlighted proteins are those previously recognized by pooled sera from adults.
Posttreatment Pretreatment
U T T NU T T N
−98
−64
−50
−36
−22
Figure 4: Immunoblots of serum samples. Comparison of pre-
(left) and post- (right) treatment immunoblots detected by their
reactivity with IgE antibodies. Identified bands are shown in boxes
and molecular weights (in kDa) are indicated at the right end.
Strips were exposed on hyperfilm for seconds (touch exposure). U:
untreated, T: treated, and N: assay control (no sample added).
studies (schistosome antigens versus allergens) would pro-
vide the spectrum of antigen recognition and inform on pos-
sible cross-reactivity.This would narrow the choice of antigen
vaccine candidates and minimise the risk of sensitization.
In this study, anti-Plasmodium responses declined in both
treated and untreated children, suggesting that this change
was not due to praziquantel treatment. Since the decline was
both in IgM responses directed against the schizont (marker
of exposure to Plasmodium infection) and IgG responses
directed against the vaccine candidates MSP-1 and MSP-2,
it is likely that the decline was reflecting normal dynam-
ics of Plasmodium antibodies in the absence of infection.
Levels of antibodies to several Plasmodium antigens vary
with the seasonality of parasite transmission, often being
higher during periods of high transmission than at the
end of a low transmission season [47]. Furthermore, levels
of anti-Plasmodium antibodies directed against both crude
and recombinant antigens tend to be higher in individuals
carrying parasites than in those without parasites [47]. The
region of Zimbabwe where the present study was conducted
is mesoendemic for malaria with an incidence of 0.2 to 10
cases/1000/year [48]. The absence of Plasmodium parasites
on blood smears of participants in this study and the decline
in the levels of anti-Plasmodium antibody responses may
therefore reflect the end of a malaria transmission season in
this area (at the time of sample collection).
In the present study, therewas no significant difference for
Derp1 specific antibodies between schistosome egg positive
and negative children at baseline. Following treatment, Derp1
specific IgE and IgG4 were significantly increased, resulting
in the ratio IgE/IgG4 (which is associated with allergic
reactivity [49]) being not significantly changed. Hagel and
colleagues indicated that a certain “threshold” is required for
parasite infection to suppress allergic reactivity [50], consis-
tent with findings from animal models [51]. The low levels
of infections in the present study population would there-
fore explain the absence of significant changes in the ratio
IgE/IgG4 against Derp 1 allergen. The increase in allergen-
specific IgE responses in treated childrenmay be due to cross-
reactivity since levels of these antibodies directed against
schistosome antigens also increased following treatment.
However, cross-reactivity cannot explain the increase in IgG4
against Derp1 in treated and, to a lesser extent, in untreated
children, since the anti-schistosome IgG4 declined. Changes
in antimite IgG4 antibodies following seasonal changes in
natural exposure to house dust mites have previously been
reported [52]. Investigations on natural temporal variations
in levels of exposure to mite were beyond the scope of this
study but this finding requires further investigation.
The current study presents the limitation that the sample
size was small, which could have affected the statistical
power. This was due to the limited accessibility of these
young children in terms of blood collection, and also because
treatment has only recently started in this age group. Never-
theless, this study is one of the first to demonstrate a boost,
due to praziquantel treatment, in anti-schistosome immune
responses in pre-school age children.
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5. Conclusion
Taken together, findings from this study suggest that praz-
iquantel treatment of preschool children has comparable
effects to those reported in studies on older children and
adults, boosting antibody responses associated with putative
resistance to schistosome infection/reinfection six weeks
following chemotherapy. Furthermore, serological recogni-
tion of schistosome antigens was enhanced following praz-
iquantel treatment in these young children, and recognized
antigens are associated with the development of acquired
protective immunity. Praziquantel treatment did not have a
significant effect on Plasmodium-specific responses, which
showed temporal fluctuation in both untreated and treated
individuals. Furthermore, PZQ treatment did not signifi-
cantly alter allergen-specific responses which would mediate
pathology in allergic disease. Thus, the study suggests that
pre-school age children may also benefit immunologically
from praziquantel treatment.
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